What is Vapogenix?
Vapogenix is a specialized healthcare innovator focused on the development of non-opioid, rapid-onset, and long-lasting pain therapies. By leveraging formulated volatile anesthetics, the company is carving out a distinct market position in the pain management space, directly addressing the urgent need for effective, non-addictive alternatives to traditional opioid medications. Their therapeutic approach is designed to provide clinicians and patients with safer, more reliable options for managing acute and chronic pain, thereby mitigating the systemic risks associated with current standard-of-care treatments. As a player in the biopharmaceutical industry, Vapogenix combines advanced chemical formulation with a clear clinical objective to disrupt the status quo of pain relief.
How much funding has Vapogenix raised?
Vapogenix has raised a total of $20.3M across 5 funding rounds:
Series A
$3.3M
Private Equity
$2.1M
Series B
$5.1M
Series C
$8.2M
Private Equity
$1.6M
Series A (2013): $3.3M, investors not publicly disclosed
Private Equity (2014): $2.1M, investors not publicly disclosed
Series B (2015): $5.1M supported by Pamoja Capital and GPG Ventures
Series C (2016): $8.2M featuring Pamoja Capital
Private Equity (2017): $1.6M, investors not publicly disclosed
Key Investors in Vapogenix
Pamoja Capital
Pamoja Capital is a growth strategy partner that empowers its investees to accelerate their business development with confidence. Founded in 2006 by John McCall MacBain, the firm consists of a global team dedicated to promoting sustainable growth through long-term investments, strategic advice, and mentoring.
GPG Ventures
Green Park & Golf Ventures is a Dallas-based venture capital firm with over 60 years of operational and financial experience, focusing on investment opportunities in medical-related start-ups. The firm seeks to provide strategic solutions and financial backing to companies that demonstrate compassion, innovation, and strong management teams.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Vapogenix?
With the recent capital injection, Vapogenix is well-positioned to accelerate its clinical development pipeline and refine its commercialization strategy. The focus will likely shift toward finalizing late-stage trials and preparing for regulatory submissions, which are critical milestones for any firm operating in the high-stakes pain management market. Furthermore, the company is expected to leverage its existing network of strategic partners to enhance its market penetration and operational efficiency. As the healthcare sector continues to prioritize non-opioid solutions, Vapogenix remains a key entity to watch for potential licensing agreements or further expansion into broader therapeutic applications, ensuring that its innovative technology reaches the patients who need it most.
See full Vapogenix company page
